Nat Torkington
2008-08-05
|
[This is part of a series of posts that briefly describe the trends were currently tracking here at O'Reilly: 1, 2] Genetic analysis software and hardware used to be very expensive, only for professionals—now it's trickling down to ProAms, and soon (under 5 years) will be widespread for consumer applications. This changes how drugs are developed and applied (don't test against 500 people and say whether it "works", figure out which genetic markers indicate the people it works for and sell to those), how diseases/conditions are diagnosed and treated, and our sense of self. Expect "interesting" (in the Chinese curse sense) interactions with privacy, workplace relations, and even parenthood. Watchlist: 23andme, Hugh Reinhoff's "My Daughter's DNA". | 翻译:西门吹雪 [这是Radar系列文章的一部分,本系列会简述在O'Reilly我们正在关注的一些趋势。] 基因分析软件和硬件过去一直很昂贵,只能由专业人士掌握——现在已经为专业爱好者所用了,而且很快(5年之内)就将广泛为消费者所用。这改变了药物开发和临床应用的方式(不要再找500人测试然后说这药“能用”,而是要指出哪些基因标志表明这个药对他们有作用),改变了疾病诊断和治疗的方式,以及我们自身的感受。 关注列表: 23andme、Hugh Reinhoff的”My Daughter's DNA“。 |
Discussion